PolyPid Ltd. (NASDAQ:PYPD) Receives $12.40 Consensus Target Price from Brokerages

PolyPid Ltd. (NASDAQ:PYPD) has been assigned an average recommendation of “Buy” from the six analysts that are covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $12.40.

Several research analysts have commented on the stock. Craig Hallum reissued a “buy” rating and set a $13.00 price objective (down previously from $15.00) on shares of PolyPid in a report on Thursday, August 14th. Wall Street Zen raised shares of PolyPid from a “sell” rating to a “hold” rating in a report on Friday, September 26th. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price target on shares of PolyPid in a report on Wednesday, August 13th. JMP Securities lowered their price target on shares of PolyPid from $16.00 to $14.00 and set a “market outperform” rating for the company in a report on Tuesday, June 17th. Finally, Roth Capital reaffirmed a “buy” rating on shares of PolyPid in a report on Thursday, August 14th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in PolyPid stock. Lumbard & Kellner LLC purchased a new stake in PolyPid Ltd. (NASDAQ:PYPD) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 38,200 shares of the company’s stock, valued at approximately $135,000. Lumbard & Kellner LLC owned about 0.24% of PolyPid at the end of the most recent quarter. 26.47% of the stock is currently owned by institutional investors and hedge funds.

PolyPid Stock Up 0.9%

PYPD opened at $3.37 on Thursday. The firm has a 50-day simple moving average of $3.43 and a two-hundred day simple moving average of $3.16. PolyPid has a 52 week low of $2.30 and a 52 week high of $3.93. The company has a market capitalization of $53.58 million, a PE ratio of -0.88 and a beta of 1.50.

PolyPid (NASDAQ:PYPD) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.25). As a group, sell-side analysts expect that PolyPid will post -1.79 earnings per share for the current year.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.